March 28, 2017 5:55 AM ET


Company Overview of Boston Therapeutics, Inc.

Company Overview

Boston Therapeutics, Inc., a pre-clinical and clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of carbohydrate-based therapeutic drugs and dietary supplements to address blood sugar management and inflammatory diseases. Its lead pharmaceutical drug candidates include BTI-320, a non-systemic, carbohydrate-based compound that is in Phase II clinical development to reduce post-meal elevation of blood glucose levels in Type 2 diabetic patients, pre diabetic patients; and IPOXYN, a carbohydrate-based, injectable drug, which is in pre-clinical stage to prevent necrosis, or cell death, as well as to treat hypoxic conditions, such as diabetic foot...

233 Needham Street

Suite 300

Newton, MA 02464

United States

Founded in 2009

1 Employees



Key Executives for Boston Therapeutics, Inc.

Boston Therapeutics, Inc. does not have any Key Executives recorded.

Boston Therapeutics, Inc. Key Developments

Boston Therapeutics, Inc. Appoints Carl W. Rausch as Director

On November 23, 2016, Carl W. Rausch was appointed by Boston Therapeutics, Inc. to serve as a director of the Company. Mr. Rausch is the Chief Executive Officer of the Company. From 2006 to 2008, Mr. Rausch was a principal with Biotechnology Partners, which provided advisory services to biotechnology clients. Mr. Rausch served as the Vice Chairman and Chief Technical Officer of Biopure Corporation from 2002 to 2005. Mr. Rausch cofounded Biopure in 1984. From 1984 until 2002, Mr. Rausch served as Chairman and Chief Executive Officer.

Alan M. Hoberman Resigns as Director of Boston Therapeutics, Inc

On November 14, 2016, Alan M. Hoberman, Ph.D. provided Boston Therapeutics, Inc. with a letter of resignation dated September 15, 2016, pursuant to which Mr. Hoberman resigned as a director of the Company.

Boston Therapeutics, Inc. expected to report Fiscal Year 2016 results on March 27, 2017. This event was calculated by Capital IQ (Created on November 11, 2016).

Boston Therapeutics, Inc. expected to report Fiscal Year 2016 results on March 27, 2017. This event was calculated by Capital IQ (Created on November 11, 2016).

Similar Private Companies By Industry

Company Name Region
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States
7 Oaks Pharmaceutical Corp. United States

Recent Private Companies Transactions

Private Placement
August 12, 2016

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Boston Therapeutics, Inc., please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at